Technical Analysis for OLMA - Olema Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 11.08 | -4.07% | -0.47 |
OLMA closed down 4.07 percent on Monday, March 18, 2024, on 1.98 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
NR7-2 | Range Contraction | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Below Lower BB | Weakness | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
200 DMA Resistance | Bearish | -4.07% | |
Volume Surge | Other | -4.07% |
Alert | Time |
---|---|
Possible NR7 | about 13 hours ago |
1.5x Volume Pace | about 17 hours ago |
Down 5% | about 17 hours ago |
Down 3% | about 17 hours ago |
Fell Below Lower Bollinger Band | about 17 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/07/2024
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Breast Cancer Treatment Of Breast Cancer Targeted Therapy Epidermal Growth Factor Receptor Hormones Her2 Her2/Neu Estrogen Antiestrogens Estrogen Receptor Selective Estrogen Receptor Degraders Fulvestrant
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Breast Cancer Treatment Of Breast Cancer Targeted Therapy Epidermal Growth Factor Receptor Hormones Her2 Her2/Neu Estrogen Antiestrogens Estrogen Receptor Selective Estrogen Receptor Degraders Fulvestrant
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 17.7911 |
52 Week Low | 3.0 |
Average Volume | 812,010 |
200-Day Moving Average | 11.76 |
50-Day Moving Average | 13.14 |
20-Day Moving Average | 13.21 |
10-Day Moving Average | 12.71 |
Average True Range | 1.15 |
RSI (14) | 34.64 |
ADX | 20.08 |
+DI | 13.31 |
-DI | 27.80 |
Chandelier Exit (Long, 3 ATRs) | 12.10 |
Chandelier Exit (Short, 3 ATRs) | 14.39 |
Upper Bollinger Bands | 15.28 |
Lower Bollinger Band | 11.14 |
Percent B (%b) | -0.02 |
BandWidth | 31.28 |
MACD Line | -0.57 |
MACD Signal Line | -0.25 |
MACD Histogram | -0.3204 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 12.17 | ||||
Resistance 3 (R3) | 12.25 | 11.96 | 11.99 | ||
Resistance 2 (R2) | 11.96 | 11.68 | 11.92 | 11.93 | |
Resistance 1 (R1) | 11.52 | 11.51 | 11.38 | 11.44 | 11.87 |
Pivot Point | 11.24 | 11.24 | 11.16 | 11.20 | 11.24 |
Support 1 (S1) | 10.80 | 10.96 | 10.65 | 10.72 | 10.29 |
Support 2 (S2) | 10.51 | 10.79 | 10.47 | 10.23 | |
Support 3 (S3) | 10.07 | 10.51 | 10.17 | ||
Support 4 (S4) | 9.99 |